IMPEDIMED LIMITED — Capital/Financing Update 2020

Mar 30, 2020

31 March 2020

==> picture [129 x 31] intentionally omitted <==

ASX ANNOUNCEMENT

ImpediMed Secures Order from Large US Oncology Care Network

Brisbane, Australia – ImpediMed Limited (ASX.IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), is pleased to announce the first order of 16 units under the recently announced national purchasing agreement with a U.S. oncology care network for its SOZO[®] Digital Health Platform and Lymphoedema Prevention Program.

“The initial order of 16 SOZO units will establish a comprehensive Lymphoedema Prevention Program in key centres from this nationally recognized oncology care network,” said Richard Carreon, Managing Director and CEO of ImpediMed. “We believe these centres will develop the model from which we will jointly expand our program nationally.”

The national purchasing agreement, which was announced on 23 March 2020, allows 1,200 physicians at 470 cancer treatment locations across the U.S. access to SOZO and ImpediMed’s BIS (L-Dex[®] ) lymphoedema assessment. Together, these physicians treat over 1 million patients annually.

The Lymphoedema Prevention Program utilises ImpediMed's Test, Trigger, Treat™ protocol for early detection and intervention of cancer-related lymphoedema. Routine lymphoedema testing of cancer survivors uses the company's SOZO device with BIS (LDex) technology. A significant increase in a patient's L-Dex score is a trigger to evaluate the patient and initiate intervention. ImpediMed's PREVENT Trial, the largest multi-site, randomised controlled trial ever performed to study lymphoedema prevention, showed that this protocol resulted in a 95% reduction in lymphoedema progression at one year.

Currently, one in three at-risk cancer survivors will develop secondary lymphoedema related to their cancer treatment, costing the U.S. healthcare system approximately $7 billion every year. The aim of the Lymphoedema Prevention Program is to help educate healthcare providers and patients that with the proper protocols in place, lymphoedema can be detected and managed before it becomes a debilitating chronic condition. Learn more at www.preventlymphedema.com.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor Relations Contact: Media Contact: Mike Bassett, ImpediMed Kyahn Williamson, WE Buchan T : +61 407 431 432 T: +61 3 9866 4722 E: mbassett@impedimed.com E: kwilliamson@we-worldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.